D. E. Shaw & Co., Inc. Relmada Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.45 - $4.22 $21,631 - $37,258	-8,829 Reduced 45.33%	10,649 $44,000
Q3 2023 Nov 14, 2023	SELL	$2.48 - $3.79 $57,632 - $88,075	-23,239 Reduced 54.4%	19,478 $58,000
Q2 2023 Aug 14, 2023	SELL	$2.22 - $3.54 $2,763 - $4,407	-1,245 Reduced 2.83%	42,717 $105,000
Q1 2023 May 15, 2023	BUY	$2.24 - $4.76 $63,369 - $134,660	28,290 Added 180.51%	43,962 $99,000
Q4 2022 Feb 14, 2023	SELL	$2.17 - $35.84 $135,698 - $2.24 Million	-62,534 Reduced 79.96%	15,672 $54,000
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $1.43 Million - $2.9 Million	78,206 New	78,206 $2.9 Million
Q2 2022 Aug 15, 2022	SELL	$16.5 - $30.34 $173,035 - $318,175	-10,487 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $175,342 - $283,044	10,487 New	10,487 $283,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $11.7M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.